

De Novo Mutations in Synaptic Transmission Genes Including *DNM1* Cause Epileptic Encephalopathies

EuroEPINOMICS-RES Consortium,* Epilepsy Phenome/Genome Project, and Epi4K Consortium

Emerging evidence indicates that epileptic encephalopathies are genetically highly heterogeneous, underscoring the need for large cohorts of well-characterized individuals to further define the genetic landscape. Through a collaboration between two consortia (EuroEPINOMICS and Epi4K/EPGP), we analyzed exome-sequencing data of 356 trios with the “classical” epileptic encephalopathies, infantile spasms and Lennox Gastaut syndrome, including 264 trios previously analyzed by the Epi4K/EPGP consortium. In this expanded cohort, we find 429 de novo mutations, including de novo mutations in *DNM1* in five individuals and de novo mutations in *GABBR2*, *FASN*, and *RYR3* in two individuals each. Unlike previous studies, this cohort is sufficiently large to show a significant excess of de novo mutations in epileptic encephalopathy probands compared to the general population using a likelihood analysis ($p = 8.2 \times 10^{-4}$), supporting a prominent role for de novo mutations in epileptic encephalopathies. We bring statistical evidence that mutations in *DNM1* cause epileptic encephalopathy, find suggestive evidence for a role of three additional genes, and show that at least 12% of analyzed individuals have an identifiable causal de novo mutation. Strikingly, 75% of mutations in these probands are predicted to disrupt a protein involved in regulating synaptic transmission, and there is a significant enrichment of de novo mutations in genes in this pathway in the entire cohort as well. These findings emphasize an important role for synaptic dysregulation in epileptic encephalopathies, above and beyond that caused by ion channel dysfunction.

Introduction

Epileptic encephalopathies (MIM 308350) comprise a range of severe epilepsy syndromes determined by age of onset, seizure types, developmental and clinical course, and electroencephalographic findings.¹ Infantile spasms are one of the most common seizure types seen in epileptic encephalopathies, and in combination with hypsarrhythmia on EEG and developmental regression define West syndrome. In some individuals, West syndrome evolves to Lennox-Gastaut syndrome, characterized by multiple seizure types including atonic and tonic seizures and generalized slow-spike-wave activity on EEG. Both entities are considered prototypic epileptic encephalopathies.

An underlying genetic cause has been shown in a growing proportion of persons with epileptic encephalopathies. Many causal mutations arise de novo.^{2–7} Our earlier exome-sequencing study of 264 trios identified de novo mutations in seven genes reported at the time in the Mendelian Inheritance in Man (OMIM) database as linked to epileptic encephalopathy (*CDKL5* [MIM 300203], *KCNQ2* [MIM 602235], *KCNT1* [MIM 608167], *SCN1A* [MIM 182389], *SCN2A* [MIM 182390], *SCN8A* [MIM 600702], and *STXBPI* [MIM 602926]) and provided clear evidence of pathogenicity for de novo mutations in two not previously implicated genes, *ALG13* (MIM 300776) and *GABRB3* (MIM 137192).² Although we found multiple additional candidate genes affected by de novo mutations, statistical power was insufficient to implicate a pathogenic role for these genes.² By combining samples from two international consortia, we now analyze a joint cohort of 356 proband-parent trios with infantile spasms or Lennox-Gastaut syndrome to search for additional causal de novo mutations.

Subjects and Methods

Study Subjects and Procedure of Exome Sequencing

Three epileptic encephalopathy cohorts were evaluated in this study: (1) Epilepsy Phenome/Genome Project (EPGP) cohort 1 ($n = 264$ trios) used in the previously published paper,² (2) new EPGP cohort 2 ($n = 73$ trios), and (3) EuroEPINOMICS-RES cohort ($n = 19$ trios). The study was approved by the local ethics committee of each participating center. Parents or the legal guardian of each proband signed an informed consent form for participation. The EPGP cohort inclusion criteria have been reported previously.² Proband recruitment through the EuroEPINOMICS-RES consortium for the project on nonlesional epileptic spasms (NLES) were enrolled by clinical sites in 18 different European countries. Genomic DNA of the individuals was extracted from peripheral blood according to standard procedures. All phenotypic data were entered in the web-based platform Cartagenia-BENCH, which was adapted for this study. Inclusion criteria included documented infantile spasms with onset in the first 2 years of life, normal routine metabolic screening, and exclusion of causal structural abnormalities on MRI of the brain. Most probands had undergone testing for known genetic causes of infantile spasms, but this was not required for study inclusion. Individuals with a family history of epilepsy in first-degree relatives were excluded. Detailed exome-sequencing and data analysis methods are provided in the legend of [Table S1](#) available online.

Trio-Specific Callable Real-Estate

Since the ability to call a de novo mutation requires that all three individuals comprising the trio are well sequenced, we calculated the percent of the exome and individual genes, as defined by the consensus coding sequence (CCDS release 9, GRCh37.p5) and the 2 bp flanking splice sites, where each base was sequenced at least 10-fold with a multisampling (GATK) raw phred-scaled confidence score of ≥ 20 in the presence or absence of a variant. These

*Correspondence: euroepinomics-RES@ua.ac.be

<http://dx.doi.org/10.1016/j.ajhg.2014.08.013>. ©2014 by The American Society of Human Genetics. All rights reserved.

estimates for callable real-estate were incorporated into the architecture and gene-enrichment analyses.

Genetic Architecture Likelihood Analyses

We conducted a likelihood analysis of parameters describing the genetic architecture of epileptic encephalopathies, including the relative risk (γ) and proportion of the exome related to epileptic encephalopathies (η). Because there were substantial differences in sequenced regions across the different exome-sequencing methods used in this study, we adapted our previously proposed likelihood model² to incorporate the sequence-specific mutation rate for the individual proband's callable real-estate. This likelihood can be written as

$$L(\gamma, \eta) = \prod_i \left\{ \frac{\lambda_i^{x_i} e^{-\lambda_i} [\gamma + (1 - \gamma)(1 - c_\eta)^{x_i}]}{x_i! \gamma + (1 - \gamma)e^{-\lambda_i c_\eta}} \right\}, \quad (1)$$

where x_i and λ_i are the de novo counts and mutation rate, respectively, for the i th trio. As in previous analyses, C is assumed to be a known constant taking the value of 0.25. Point estimates were obtained by optimizing Equation 1 and likelihood ratio tests were computed by comparing the log-likelihood at this optimum to the value obtained under the null hypothesis. Marginal confidence intervals for η and γ were derived based on a profile likelihood calculated from the equation above.

“Hot-Zone” Analysis

To further assess the likelihood of pathogenicity of mutations, we considered two scores for each de novo single-nucleotide variant (SNV): the gene-level residual variation intolerance score (RVIS) assesses the intolerance of genes to functional genetic variation⁸ and the variant-level score assesses the probability that a given variant damages protein function. For the variant-level score, we use PolyPhen-2 (HumVar) to score missense variants. Synonymous and loss-of-function (nonsense and splice acceptor/donor) mutations were scored 0 and 1, respectively. For comparison, we also assessed de novo mutations in previously published control trios that reported at least one protein-coding de novo mutation ($n = 411$).^{9–14,16} The de novo mutations previously reported in controls were subjected to the same filtering criteria we used in this study, including presence in the CCDS protein-coding regions or in the 2 bp flanking splice donor and acceptor sites and absence from control cohort and ESP6500SI database. We also reassessed variant function using the same annotation pipeline used for the epileptic encephalopathy probands. Overlapping control samples, which were reported across multiple studies, were only considered once.

For each case and control sample that reported multiple de novo mutations, we considered only the single most damaging de novo mutation based on the shortest Euclidian distance from the most damaging coordinate [1,0] in the 2D space that is constructed based on the variant-level vector (PolyPhen-2 score) along the x axis and the gene-level vector (RVIS percentile score) along the y axis (Figure 1).

A two-tailed Fisher's exact was used to test whether the single most damaging de novo mutation found in cases preferentially lay in the “hot zone,” defined by a PolyPhen-2 score of ≥ 0.95 and RVIS $\leq 25^{\text{th}}$ percentile,⁸ in comparison to the single most damaging de novo mutations in previously published control trios.

Calculation of the Gene-Specific Mutation Rate

The probabilities of getting greater than or equal de novo point mutations by chance when considering the observed numbers of de novo point mutations were calculated using procedures similar to the one that we introduced previously,² with one minor modification: for the X chromosome, instead of calculating the average mutation rate and multiplying it by the number of gene copies, the mutation rate was calculated as the sum of the diploid rate in each female trio and the haploid rate in each male trio (Table 1).

Determination of “Solved” Epileptic Encephalopathy Trios

To determine what proportion of the 356 epileptic encephalopathy probands are currently explained by an identified de novo mutation, we first generated a list of genes in which mutations with high confidence cause an epileptic encephalopathy (further referred to as “epileptic encephalopathy genes”). We searched the OMIM database (January 2014) as well as several recent publications to obtain a comprehensive list of putative epileptic encephalopathy genes. We considered five categories of genes: (1) OMIM “epileptic encephalopathy (EIEE),” $n = 18$; (2) OMIM “Dravet Syndrome,” $n = 1$; (3) OMIM Neurological Clinical Synopsis containing “epileptic encephalopathy” in disorders with a “known molecular basis,” $n = 8$; (4) genes implicated in OMIM due to “epileptic encephalopathy” in the gene summaries, $n = 19$; and (5) genes implicated in epileptic encephalopathy in the recent literature, $n = 6$ (*ALG13*,² *DNMI* [MIM 602377], *GABRA1*¹⁵ [MIM 137160], *GABRB3*,² *GRIN2B*⁷ [MIM 138252], and *SLC35A2*⁵ [MIM 314375]). For the first two categories, if the mode of inheritance was recessive or if the first reported allelic variant in OMIM was published before 2010, we considered these definitive EE genes ($n = 15$; *ARHGEF9* [MIM 300429], *ARX* [MIM 300382], *CDKL5*, *KCNQ2* [MIM 602235], *PCDH19* [MIM 300460], *PLCB1* [MIM 607120], *PNKP* [MIM 605610], *PNPO* [MIM 603287], *SCN1A*, *SCN2A*, *SLC25A22* [MIM 609302], *ST3GAL3* [MIM 606494], *STXBP1*, *SZT2* [MIM 615463], and *TBC1D24* [MIM 613577]). For all remaining genes on this comprehensive list of putative epileptic encephalopathy genes, a panel of clinicians reviewed the specific phenotypic details to determine the relevance to epileptic encephalopathy specifically. This highlighted 13 genes of interest, including eight genes from category 1, two from category 3, one from category 4, and six from category 5 (Table S4). We then applied the test for a significant excess of de novo mutations in these genes to statistically analyze their association with epileptic encephalopathy (Table S4). Of the 13 tested genes, 11 showed significant association with epileptic encephalopathy (*ALG13*, *CHD2* [MIM 602119], *DNMI*, *GABRA1*, *GABRB3*, *GNAO1* [MIM 139311], *GRIN2A* [MIM 138253], *KCNT1*, *SCN8A*, *SLC35A2*, and *SYNGAP1* [MIM 603384]), giving us a total of 26 high-confidence epileptic encephalopathy genes (11 newly tested genes + 15 original “definitive epileptic encephalopathy genes”). A full list of contributing variants and corresponding literature references is provided in Table S4.

Gene List Enrichment Analyses

To determine whether our list of de novo mutations was preferentially located in genes contained in a set of relevant gene lists, we used a previously published method.² In brief, a binomial probability calculation was adopted to determine whether the de novo mutations identified in this cohort of epileptic encephalopathy




Figure 1. Hot-Zone Analysis

Illustrates where de novo single-nucleotide mutations reside along the variant-level vector (x axis: PolyPhen-2 HumVar score) and the gene-level vector (y axis: RVIS percentile score). We identified 411 controls^{9–14,16} (A, adapted from Zhu et al.³⁴) and 232 epileptic encephalopathy cases (B) that reported at least one single-nucleotide de novo mutation. For each of the cases and controls, we plot the single most damaging single-nucleotide de novo mutation, as defined by the shortest Euclidian distance from the most damaging coordinate [1,0]. The hot zone (red shading) is defined as the region that reflects a PolyPhen-2 score ≥ 0.95 and a RVIS percentile score $\leq 25\%$. Details for all hot-zone de novo mutations are available in Table S1. Among the case hot-zone insert we flag with red the hot-zone de novo mutations that occur in the epileptic encephalopathy gene list as described in the panel.

proband were selectively enriched within the well-sequenced coding sequence of genes within a particular gene list. This process corrects each gene list not only for the protein-coding real estate (size) of genes, but also for the average “callable real estate” across all trios.

We performed two additional tests to confirm the relationship of the observed gene list enrichments among genes harboring a de novo mutation in epileptic encephalopathy probands. First, for each gene list, we calculated the matching exact binomial test based on de novo single-nucleotide mutations identified among controls, corrected for corresponding CCDS protein-coding sizes.^{9–14,16} Then, for each gene list, we also directly compared the rate of overlapping single-nucleotide de novo mutations between our epileptic encephalopathy cohort and a control cohort.

For this direct comparison we used a two-tail Fisher’s exact test to determine whether there was a significantly increased frequency of de novo mutations overlapping a gene list among either the cases or controls.

Protein-Protein Interaction Network Analyses

Ingenuity Pathway Analysis (Ingenuity Systems) was used to assess connectivity of proteins harboring a de novo substitution. The requirements for assessing protein-protein interconnectivity were experimentally observed interactions. The permitted interaction types were: protein-protein, protein-DNA, activation, inhibition, phosphorylation, and ubiquitination. As described previously,² preferential gene list enrichment among the network, compared

Table 1. Recurrently Mutated Genes and Probability of Observing Multiple De Novo Mutations in a Cohort of 356 Trios only Considering Substitutions

Gene	Chr	Average Effectively Sequenced Length (bp)	Average Mutation Rate	Number of De Novo Mutations	p Value ^a
<i>ALG13</i> ^b	X	1,134.24	1.57×10^{-5}	2	$8.07 \times 10^{-12***}$
<i>CDKL5</i>	X	2,860.67	3.97×10^{-5}	3	$1.33 \times 10^{-6*}$
<i>CHD2</i> ^c	15	5,369.04	7.34×10^{-5}	2	1.32×10^{-3}
<i>DNM1</i>	9	2,334.48	4.58×10^{-5}	5	$2.99 \times 10^{-10***}$
<i>EASN</i>	17	6,139.81	1.30×10^{-4}	2	4.05×10^{-3}
<i>GABBR2</i>	9	2,560.29	4.43×10^{-5}	2	4.86×10^{-4}
<i>GABRB3</i>	15	1,263.05	2.02×10^{-5}	4	$1.75 \times 10^{-9***}$
<i>GNAO1</i>	16	1,319.68	2.49×10^{-5}	2	1.55×10^{-4}
<i>HDAC4</i> ^d	2	2,769.92	6.04×10^{-5}	2	9.00×10^{-4}
<i>KCNQ2</i>	20	1,708.42	3.84×10^{-5}	2	3.66×10^{-4}
<i>PIK3API</i> ^e	10	2,431.02	4.01×10^{-5}	2	3.99×10^{-4}
<i>RANGAP1</i> ^f	22	1,557.37	2.48×10^{-5}	2	1.54×10^{-4}
<i>RYR3</i>	15	14,777.56	2.18×10^{-4}	2	N/A ^g
<i>SCN1A</i> ^b	2	6,067.97	8.07×10^{-5}	7	$3.91 \times 10^{-13***}$
<i>SCN2A</i> ^b	2	5,899.52	7.69×10^{-5}	3	$2.07 \times 10^{-9***}$
<i>SCN8A</i>	12	5,858.57	8.35×10^{-5}	2	1.70×10^{-3}
<i>SLC35A2</i> ^h	X	1,107.91	1.95×10^{-5}	2	4.86×10^{-5}
<i>STXBP1</i>	9	1,922.03	3.22×10^{-5}	5	$5.20 \times 10^{-11***}$
<i>TTN</i> ⁱ	2	104,698.88	1.35×10^{-3}	2	2.50×10^{-1}

^aAdjusted α is equivalent to $0.05 / 18,091 = 2.76 \times 10^{-6}$, indicated by single asterisk; $0.01 / 18,091 = 5.53 \times 10^{-7}$, indicated by double asterisk; or $0.001 / 18,091 = 5.53 \times 10^{-8}$, indicated by triple asterisk.

^bExact same mutation was observed in multiple unique individuals in this gene; in these instances, a p value reflecting probability for site-specific recurrent mutations was also calculated. The smaller p value is shown in the table.

^cMIM 602119.

^dMIM 605314.

^eMIM 607942.

^fMIM 602362.

^gMutation rates for small insertion-deletion de novo mutations are not able to be estimated, therefore probability could not be estimated.

^hMIM 314375.

ⁱMIM 188840.

to outside the interconnected network, was assessed using a two-tailed Fisher's exact test.

Results

Distribution of De Novo Mutations in the Epileptic Encephalopathy Cohort

In the 356 trios, 29.18 ± 1.07 Mb (range 25.50–31.06 Mb) of the CCDS and associated splice sites were sufficiently sequenced in each family to detect a de novo mutation. These estimates were similar between the two cohorts (Epi4K, 29.18 ± 1.10 Mb [range 25.50–31.06 Mb]; EuroEPINOMICS-RES, 29.20 ± 0.25 Mb [range 28.77–29.54 Mb]). We identified a total of 429 de novo mutations in the 356 individuals analyzed (mean 1.2 per person). Of these, 58 (13.5%) are predicted loss-of-function (nonsense, frame-shift insertion-deletion, splice site) mutations and 281 (65.5%) are missense or in-frame deletions (Table

S1). The frequency of loss-of-function mutations is significantly higher than the 7.1% observed in exome-sequenced control trios,^{9–14,16} (exact binomial test, $p = 3.0 \times 10^{-6}$).

Using a likelihood analysis, we compared the distribution of the number of de novo mutations per individual in probands with epileptic encephalopathies (Figure S1) to the expected distribution in a control population. We find that individuals with epileptic encephalopathies have significantly more exonic de novo mutations compared to controls ($p = 1.9 \times 10^{-4}$, Figure S2).

We show that by taking the single most damaging de novo mutation per individual in a population of controls,^{9–14,16} 12% of de novo SNVs fall in the hot zone (Figure 1A). In contrast, among individuals with epileptic encephalopathies, the proportion of all single most damaging de novo mutations in the hot zone is 32%. This translates into an excess of 46 de novo mutations in the hot zone in our sample of probands with epileptic encephalopathies compared to control expectations

(Figure 1B, two-tailed Fisher's exact test, $p = 3.0 \times 10^{-9}$). Considering only intolerant genes in the likelihood analysis ($RVIS \leq 25^{\text{th}}$ percentile), we likewise see an excess of de novo mutations in intolerant genes ($p = 4.1 \times 10^{-4}$, Figure S2). From this analysis, we estimate that 2.8% ($\eta = 0.028$; CI = 0–1) of the ~4,000 intolerant genes ($RVIS \leq 25\%$) in the genome contribute to epileptic encephalopathy risk. Because the confidence interval limits reliability of the parameter estimate, we simulated the sample size needed to reduce the boundaries of the CI. We found that sample sizes approximately four times the size of the current cohort would be expected to reduce the CI to half its current size.

Screen for Genes Not Previously Implicated in Epileptic Encephalopathy

We found 19 genes with a de novo mutation in two or more probands (Table 1). Seven genes carried a significant excess of de novo mutations, independently supporting their roles in epileptic encephalopathies (Table 1, Figure S3), including six genes known to carry epileptic encephalopathy-causing mutations (*ALG13*,² *CDKL5*,¹⁷ *GABRB3*,² *SCN1A*,⁴ *SCN2A*,¹⁸ and *STXBP1*¹⁹) and one, *DNM1*, not previously linked to disease. Clinical features of persons with a de novo mutation in *DNM1* are summarized in Table 2. We note that our method analyzing the likelihood of seeing multiple de novo mutations in the same gene in the aggregate epileptic encephalopathy cohort does not take into account that some of the genes with mutations in more than one individual might be particularly associated with specific epileptic encephalopathy subphenotypes.

Protein-Protein Interaction Network Analyses and Gene Enrichment Analysis

The addition of de novo mutation data from 92 samples to our original investigation on 264 probands² shows an extension of the interconnected network to 139 interacting proteins, and we continue to see an enrichment of known epileptic encephalopathy genes (Table S3). Strikingly, among the 139 genes forming this protein network, 42 (30.2%) encode proteins annotated to the “synaptic junction transmission” gene list, as defined by Ingenuity Pathway Analysis (IPA, Ingenuity Systems), including *DNM1* and two other genes with multiple de novo mutations in this study (*GABBR2* [MIM 607340] and *RYR3* [MIM 180903]) (Figures 2 and S4). Furthermore, of the 26 definitive epileptic encephalopathy genes, as defined in Supplemental Methods, 13 genes (*ARHGEF9*, *DNM1*, *GABRA1*, *GABRB3*, *GNAO1*, *GRIN2A*, *KCNQ2*, *PLCB1*, *SCN1A*, *SCN2A*, *SCN8A*, *STXBP1*, *SYNGAP1*) encode proteins that are part of IPA's “synaptic junction transmission” gene list. Given these patterns, we first assessed whether the single nucleotide de novo mutations found in the 356 probands were preferentially occurring within the 1,085 genes annotated to synaptic junction transmission by IPA and found significant enrichment ($p = 7.3 \times$

10^{-14}) (Table S5). Interestingly, we find enrichment for synaptic transmission genes even discounting all genes encoding ion channels ($p = 3.1 \times 10^{-6}$), but the reverse is not true ($p = 0.38$).

Consistent with earlier studies, we also find that de novo mutations are preferentially drawn from a number of other groups of genes, including fragile X mental retardation protein (FMRP)-regulated genes ($p = 3.9 \times 10^{-12}$)^{2,20} and Mouse Genome Informatics (MGI) seizure ortholog genes ($p = 3.7 \times 10^{-19}$).²¹ We see no similar preferential enrichment of de novo single-nucleotide mutations among any of the above gene lists when looking at de novo mutations observed in control trios (Table S5).

Discussion

Infantile spasms and Lennox-Gastaut syndrome represent classical phenotypes of epileptic encephalopathy. Analysis of exome data of 356 trios with these severe epileptic disorders shows an excess of exonic de novo mutations compared to control trios. While a number of studies report de novo mutations in neuropsychiatric diseases,^{10–13,22,23} they did not show a statistically significant overall excess (genome-wide) of de novo mutations. Furthermore, we show that there is an excess of de novo mutations in mutation-intolerant genes and in a hot zone defined by a PolyPhen-2 score of ≥ 0.95 and $RVIS^8 \leq 25^{\text{th}}$ percentile in probands. These findings underscore the prominent role of de novo mutations in the etiology of epileptic encephalopathies. Pathway analysis further shows that there is a strong enrichment of de novo mutations in genes annotated to synaptic junction transmission, even when excluding ion channel genes. Disturbance of synaptic transmission thus seems to be a key factor in the pathogenesis of epileptic encephalopathies.

In the current data set, we find five individuals with a de novo missense mutation in *DNM1*, one of the genes involved in synaptic transmission. In our earlier study, de novo mutations in *DNM1* were identified in two persons, but statistical evidence was insufficient to support pathogenicity.² In this larger cohort we now securely implicate *DNM1* as a gene in which mutations cause epileptic encephalopathy. All five probands with de novo mutations in *DNM1* had infantile spasms with onset between 2 and 13 months. Four of the five persons evolved to Lennox-Gastaut syndrome. All individuals had severe to profound intellectual disability with pronounced hypotonia and absence of speech. The presence of some developmental delay prior to epilepsy onset in two probands may suggest an influence of *DNM1* on neurodevelopment independent of seizure activity.

Dynamin-1 (*DNM1*) is an exclusively brain-expressed GTPase localizing to the presynaptic terminal. It is involved in activity-dependent synaptic vesicle endocytosis and membrane recycling.²⁴ More precisely, it provides the mechanical force necessary to pinch off budding vesicles

Table 2. Clinical Features of Individuals with De Novo *DNM1* Mutations

Trio	LGskj	ISg	LGsaix	NLE516	NLE57
Mutation ^a	c.529G>C (p.Ala177Pro)	c.618G>C (p.Lys206Asn)	c.1076G>C (p.Gly359Ala)	c.709C>T (p.Arg237Trp)	c.194C>A (p.Thr65Asn)
Gender, age	F, 15 years	M, 8 years	M, 6 years	F, 13 years	M, 6 years
Exam at birth	normal	normal	normal	normal	normal
Development prior to epilepsy onset	probably normal (lost skills between 9 and 11 months)	head control 2–3 months, at 6 months some delay noted	normal	all milestones delayed	all milestones delayed
Seizure onset	7 months	6 months	2 months	12 months	13 months
Seizure type at onset	epileptic spasms	epileptic spasms	epileptic spasms	epileptic spasms	epileptic spasms
Other seizure types	atypical absences with eyelid fluttering, drop attacks, generalized tonic clonic seizures	atonic and tonic seizures	none	myoclonic, atypical absences, tonic, focal dyscognitive seizures, generalized tonic clonic seizures, obtundation status	atypical absences, tonic, focal dyscognitive seizures, obtundation status
Antiepileptic drug response	therapy resistant, longer periods of seizure freedom on vigabatrin and valproic acid	therapy resistant, some response to ketogenic diet	seizure free on ketogenic diet since age 3.5 years	therapy resistant	therapy resistant, no effect of ketogenic diet
Seizure outcome	seizure free between 3 and 8 years, then relapse	on-going frequent seizures	seizure free on ketogenic, off antiepileptic drugs	ongoing frequent seizures	ongoing frequent seizures
EEG at onset	slow background, multifocal discharges	hypsarrhythmia	high voltage bilateral slow spike-wave discharges	modified hypsarrhythmia	hypsarrhythmia
Course of EEG	slow background, slow generalized spike-wave discharges and multifocal (poly)spikes	slow background, left temporal slowing, slow generalized spike-wave discharges, diffuse (poly) spikes	not available	slow background, diffuse slow spike-wave discharges, sharp waves-slow waves; (poly)spike waves; paroxysmal fast activity	slow background, diffuse multifocal sharp waves and sharp waves-slow waves; paroxysmal fast activity
Neurological examination	mild diffuse hypotonia, mild ataxia with wide based gait, mild tremor	general hypotonia	general hypotonia	axial hypotonia, secondary microcephaly	axial hypotonia
Development at last follow up	severe intellectual disability; no speech; autism spectrum disorder, behavioral problems with self-injurious behavior	severe intellectual disability; no speech; does not walk	severe intellectual disability; no speech; does not walk; behavioral problems with self-injurious behavior	profound intellectual disability; no speech; no visual fixation; does not sit or walk	profound intellectual disability; no speech; no visual fixation; does not sit or walk
MRI	normal	normal	normal	generalized cerebral atrophy	generalized cerebral atrophy

^aAnnotated based on NCBI IDs: NM_004408.3 and NP_004399.2.




Figure 2. Primary Protein-Protein Interaction Network of 139 Interconnected Proteins

This reflects 134 proteins that are affected by de novo substitutions identified among the 356 epileptic encephalopathy probands reported here and 5 literature-introduced epileptic encephalopathy proteins (marked with an asterisk). Ingenuity Pathway Analysis (IPA) annotated “synaptic junction transmission” proteins are marked in yellow. Known epileptic encephalopathy genes, including the newly identified *DNM1*, are circled in gray. The geometric shapes reflect differing protein roles, as defined by IPA: enzyme, rhombus; ion channel, vertical rectangle; kinase, inverted triangle; ligand-dependent nuclear receptor, horizontal rectangle; phosphatase, triangle; transcription regulator, horizontal oval; transmembrane receptor, vertical oval; transporter, trapezoid; and unknown, circle.

from the synaptic membrane, and becomes essential during high levels of neuronal activity.²⁴ The expression of *DNM1* is upregulated during postnatal brain development and peaks during neurite and synapse formation.²⁵ Functionally, *DNM1* has five domains: (1) a GTPase domain that binds and hydrolyzes GTP and contains four GTP binding motifs (G1–G4), (2) a middle domain that is important for oligomerization, (3) a pleckstrin homology domain that binds lipids, (4) a GTPase effector domain that fulfills an assembly function and stimulates GTPase activity, and (5) a proline-rich domain that interacts with SH3 domains in other proteins (Figure 3).

All five *DNM1* substitutions identified in this study affect highly conserved residues (Figure 3). Four substitutions are located in the GTPase domain, and two of these lie in a G

motif (c.194C>A [p.Thr65Asn] in G1 and c.618G>C [p.Lys206Asn] in G4 [RefSeq accession numbers NM_004408.3, NP_004399.2]). The fifth substitution lies in the middle domain (Figure 3).

Several previous studies have introduced different dynamin mutant constructs into mammalian cells.^{26,27} The overall effect was an impairment of endocytosis, as was also shown for a mutant affecting the same amino acid in G1, p.Thr65Ala, which blocked hydrolysis of GTP.²⁶ Several other mutants have been shown to exert a dominant-negative effect. Of particular interest in this regard is the spontaneous substitution p.Ala408Thr (*DNM1*^{ftfl}), located in the middle domain of *DNM1*, in the so-called fitful mouse.²⁸ Mice heterozygous for the substitution present with recurrent, often intractable, seizures whereas




Figure 3. Schematic Representation of DNMI1 with Location of Substitutions and Conservation of Substitution Sites

(A) Structure of the DNMI1 protein with indication of the different domains and the G1–G4 motifs. Substitutions identified in this study are shown below the figure, the substitution in the fitful mouse above the figure. PH, pleckstrin homology; GED, GTPase effector domain; PRD, proline-rich domain.

(B) Sequence alignment in different species of the regions of the substitutions found in this study. Substitutions are highlighted in red.

homozygous mice have a more severe phenotype with ataxia and often lethal seizures. DNMI1^{ftfl} showed impaired oligomerization stalling endocytosis, and binding to wild-type DNMI1, thereby exerting a dominant-negative effect. Because the loss of DNMI1 preferentially affects inhibitory synapses,²⁴ it is possible that the stalled endocytosis leads to inefficient recycling of synaptic vesicles with impaired tonic firing at inhibitory synapses and thus seizures as a result.²⁸ It remains to be shown whether the five mutations identified in this study exert a similar dominant-negative effect.

While no other novel genes reached statistical significance, the excess of mutations among intolerant genes occurs only partially in either known or newly established genes for epileptic encephalopathies. This indicates that further genetic risk factors are present in our cohort. In particular, we identify multiple de novo mutations in *GABBR2*, *FASN* (MIM 600212), and *RYR3* (Tables S1 and S2), making them strong candidate epileptic encephalopathy genes. All three genes are among the genes most intolerant to functional variation (RVIS: *GABBR2*, 5.08%; *FASN*, 0.38%; *RYR3*, 0.06%). *GABBR2* encodes a subunit of the brain-expressed G protein coupled GABA_B receptor. Knockout mice exhibit spontaneous seizures and severe memory impairment.²⁹ Fatty acid synthase, a multifunctional protein encoded by *FASN*, plays a key role in de novo lipogenesis and is highly active in adult neural stem cells. Deletion of the gene in mice results in impairment of adult neurogenesis.³⁰ Finally, *RYR3* is a brain-expressed ryanodine receptor, responsible for calcium release from intracellular stores. *RYR3* plays a role in synaptic plasticity and *Ryr3* knockout mice exhibit impaired spatial learning.³¹

After establishing a list of 26 definite epileptic encephalopathy genes, we estimate that at least 12% (42/356) of persons with infantile spasms or Lennox-Gastaut syn-

drome have definitive disease-causing de novo mutations in protein-coding regions (Table S1). We emphasize that the method used to define this list of epileptic encephalopathy genes is highly conservative and relies only on statistical evidence supporting an excess of reported de novo SNVs in epileptic encephalopathy probands across multiple studies. It does not incorporate any assessments of the biological consequences of mutations. As a result, *GRIN2B* did not reach our threshold in this analysis, although it is clearly linked to epileptic encephalopathy when considering evidence of both the presence of mutations in selected proband cohorts and functional and electrophysiological effects of mutations.⁷

The likelihood and hot-zone analysis suggest additional causal genes beyond those securely implicated in our study. Evidence for these genes will accumulate with increasing sample sizes. This continuous increase of causally implicated genes is already illustrated by the identification of six additional genes with epileptic encephalopathy-causing mutations since the publication of the initial screen for de novo mutations in epileptic encephalopathies (*CHD2*,³ *DNMI1*, *GABRA1*,¹⁵ *GNAO1*,⁶ *SLC35A2*,⁵ and *GRIN2A*^{32,33}). In all six genes, our initial study had identified at least one de novo mutation, but we did not have definite statistical evidence for their role at the time.² In the current cohort of 356 individuals, we find additional de novo mutations in four of these new genes (*CHD2*, *DNMI1*, *GNAO1*, and *SLC35A2*, Table S1; clinical data of not previously reported persons, Table S2).

In conclusion, by combining the data from two international consortia, we demonstrate the important role of damaging de novo mutations, confirm the role of five recently described genes with epileptic encephalopathy-causing mutations, and find secure evidence for a causative role of *DNMI1* mutations in severe epileptic

encephalopathies. Moreover, we provide suggestive evidence for three other genes (*GABBR2*, *FASN*, and *RYR3*). The extent of the genetic heterogeneity associated with epileptic encephalopathies strongly motivates genome-wide screening in the clinical setting, rather than more targeted approaches. We advocate the establishment of a centralized genome data repository on epileptic encephalopathy probands to increase the speed of gene discovery in these devastating neurological disorders. Collectively, our data present evidence for a predominant role of synaptic dysregulation in epileptic encephalopathies, complementing the prevailing channelopathy paradigm in epilepsy.

Supplemental Data

Supplemental Data include four figures, six tables, consortia member affiliations, and Supplemental Acknowledgments and Author Contributions and can be found with this article online at <http://dx.doi.org/10.1016/j.ajhg.2014.08.013>.

Consortia

The members of EuroEPINOMICS-RES are Silke Appenzeller, Rudi Balling, Nina Barisic, Stéphanie Baulac, Hande Caglayan, Dana Craiu, Peter De Jonghe, Christel Depienne, Petia Dimova, Tania Djémié, Padhraig Gormley, Renzo Guerrini, Ingo Helbig, Helle Hjalgrim, Dorota Hoffman-Zacharska, Johanna Jähn, Karl Martin Klein, Bobby Koeleman, Vladimir Komarek, Roland Krause, Gregor Kuhlenbäumer, Eric Leguern, Anna-Elina Lehesjoki, Johannes R. Lemke, Holger Lerche, Tarja Linnankivi, Carla Marini, Patrick May, Rikke S. Møller, Hiltrud Muhle, Deb Pal, Aarno Palotie, Manuela Pendziwiat, Angela Robbiano, Filip Roelens, Felix Rosenow, Kaja Selmer, Jose M. Serratos, Sanjay Sisodiya, Ulrich Stephani, Katalin Sterbova, Pasquale Striano, Arvid Suls, Tiina Talvik, Sarah von Spiczak, Yvonne Weber, Sarah Weckhuysen, and Federico Zara.

The members of EPGP are Bassel Abou-Khalil, Brian K. Alldredge, Eva Andermann, Frederick Andermann, Dina Amron, Jocelyn F. Bautista, Samuel F. Berkovic, Judith Bluvstein, Alex Boro, Gregory Cascino, Damian Consalvo, Patricia Crumrine, Orrin Devinsky, Dennis Dlugos, Michael P. Epstein, Miguel Fiol, Nathan B. Fountain, Jacqueline French, Daniel Friedman, Eric B. Geller, Tracy Glauser, Simon Glynn, Kevin Haas, Sheryl R. Haut, Jean Hayward, Sandra L. Helmers, Sucheta Joshi, Andres Kanner, Heidi E. Kirsch, Robert C. Knowlton, Eric H. Kossoff, Rachel Kuperman, Ruben Kuzniecky, Daniel H. Lowenstein, Shannon M. McGuire, Paul V. Motika, Edward J. Novotny, Ruth Ottman, Juliann M. Paolicchi, Jack Parent, Kristen Park, Annapurna Poduri, Lynette Sadleir, Ingrid E. Scheffer, Renée A. Shellhaas, Elliott Sherr, Jerry J. Shih, Rani Singh, Joseph Sirven, Michael C. Smith, Joe Sullivan, Liu Lin Thio, Anu Venkat, Eileen P.G. Vining, Gretchen K. Von Allmen, Judith L. Weisenberg, Peter Widdess-Walsh, and Melodie R. Winawer.

The members of Epi4K are Andrew S. Allen, Samuel F. Berkovic, Patrick Cossette, Norman Delanty, Dennis Dlugos, Evan E. Eichler, Michael P. Epstein, Tracy Glauser, David B. Goldstein, Yujun Han, Erin L. Heinzen, Michael R. Johnson, Ruben Kuzniecky, Daniel H. Lowenstein, Anthony G. Marson, Heather C. Mefford, Sahar Esmaeeli Nieh, Terence J. O'Brien, Ruth Ottman, Stephen Petrou, Slavé Petrovski, Annapurna Poduri, Elizabeth K. Ruzzo, Ingrid E. Scheffer, and Elliott Sherr.

Acknowledgments

We are deeply grateful to the probands, their families, clinical research coordinators, and referring physicians for their participation and provision of phenotype data and DNA samples used in this study.

We thank the EPGP Administrative Core (C. Freyer, K. Schardein, R. Fahlstrom, S. Cristofaro, and K. McGovern), EPGP Bioinformatics Core (G. Nesbitt, K. McKenna, and V. Mays), staff at the Coriell Institute – NINDS Genetics Repository (C. Tarn and A. Scutti), and members of the Duke Center for Human Genome Variation (J. Bridgers, J. Keebler, H.S. Kim, S. Gewalt, J. Maia, E. Campbell, K. Cronin, L. Hong, S. Sliwa, J. Quinn, C. Mebane, E. Kazura, R. Perez-Marco, and M. Cook) for their extraordinary dedication and commitment to this work. We also thank S. Shinnar (Albert Einstein College of Medicine) and N. Risch (University of California, San Francisco) for valuable input into the creation of EPGP and Epi4K, and R. Stewart, K. Gwinn, and R. Coriveau from the National Institute of Neurological Disorders and Stroke for their careful oversight and guidance of both EPGP and Epi4K.

This work was supported by grants from the National Institute of Neurological Disorders and Stroke (The Epilepsy Phenome/Genome Project NS053998; Epi4K NS077364, NS077274, NS077303, and NS077276), The Andrew's Foundation, Finding a Cure for Epilepsy and Seizures, the Richard Thalheimer Philanthropic Fund, and the Eurocores program EuroEPINOMICS-RES of the European Science Foundation. Additional funding sources are summarized in the [Supplemental Acknowledgments](#). The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Received: June 3, 2014

Accepted: August 29, 2014

Published: September 25, 2014

Web Resources

The URLs for data presented herein are as follows:

1000 Genomes, <http://browser.1000genomes.org>
Burrows-Wheeler Aligner, <http://bio-bwa.sourceforge.net/>
CCDS, <http://www.ncbi.nlm.nih.gov/CCDS/CcidsBrowse.cgi>
ClustalW2, <http://www.ebi.ac.uk/Tools/msa/clustalw2/>
dbGaP, <http://www.ncbi.nlm.nih.gov/gap>
DeNovoGear, <http://sourceforge.net/projects/denovogear/>
Dindel, <http://www.sanger.ac.uk/resources/software/dindel/>
Ensembl Genome Browser, <http://www.ensembl.org/index.html>
EuroEPINOMICS, <http://www.euroepinomics.org>
European Genome-phenome Archive (EGA), <https://www.ebi.ac.uk/ega>
GATK, <http://www.broadinstitute.org/gatk/>
Genic Intolerance, <http://chgv.org/GenicIntolerance/>
GenomeComb, <http://genomecomb.sourceforge.net/>
HumanSplicingFinder, <http://www.umd.be/HSF/>
Mouse Genome Informatics, <http://www.informatics.jax.org/>
NHLBI Exome Sequencing Project (ESP) Exome Variant Server, <http://evs.gs.washington.edu/EVS/>
Online Mendelian Inheritance in Man (OMIM), <http://www.omim.org/>
PolyPhen-2, <http://www.genetics.bwh.harvard.edu/pph2/>
RefSeq, <http://www.ncbi.nlm.nih.gov/RefSeq>

Accession Numbers

The Epi4K exome-sequencing data reported in this paper are deposited in the Database of Genotypes and Phenotypes (dbGaP), accession number phs000654.v2.p1. The EuroEPINOMICS-RES exome-sequencing data are deposited in the European Genome-phenome Archive, accession numbers EGAS00001000190, EGAS00001000386, and EGAS00001000048.

References

1. Berg, A.T., Berkovic, S.F., Brodie, M.J., Buchhalter, J., Cross, J.H., van Emde Boas, W., Engel, J., French, J., Glauser, T.A., Mathern, G.W., et al. (2010). Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. *Epilepsia* 51, 676–685.
2. Allen, A.S., Berkovic, S.F., Cossette, P., Delanty, N., Dlugos, D., Eichler, E.E., Epstein, M.P., Glauser, T., Goldstein, D.B., Han, Y., et al.; Epi4K Consortium; Epilepsy Phenome/Genome Project (2013). De novo mutations in epileptic encephalopathies. *Nature* 501, 217–221.
3. Carvill, G.L., Heavin, S.B., Yendle, S.C., McMahon, J.M., O’Roak, B.J., Cook, J., Khan, A., Dorschner, M.O., Weaver, M., Calvert, S., et al. (2013). Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. *Nat. Genet.* 45, 825–830.
4. Claes, L., Del-Favero, J., Ceulemans, B., Lagae, L., Van Broeckhoven, C., and De Jonghe, P. (2001). De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. *Am. J. Hum. Genet.* 68, 1327–1332.
5. Kodera, H., Nakamura, K., Osaka, H., Maegaki, Y., Haginoya, K., Mizumoto, S., Kato, M., Okamoto, N., Iai, M., Kondo, Y., et al. (2013). De novo mutations in SLC35A2 encoding a UDP-galactose transporter cause early-onset epileptic encephalopathy. *Hum. Mutat.* 34, 1708–1714.
6. Nakamura, K., Kodera, H., Akita, T., Shiina, M., Kato, M., Hoshino, H., Terashima, H., Osaka, H., Nakamura, S., Tohyama, J., et al. (2013). De novo mutations in GNAO1, encoding a G α subunit of heterotrimeric G proteins, cause epileptic encephalopathy. *Am. J. Hum. Genet.* 93, 496–505.
7. Lemke, J.R., Hendrickx, R., Geider, K., Laube, B., Schwake, M., Harvey, R.J., James, V.M., Pepler, A., Steiner, I., Hörtnagel, K., et al. (2014). GRIN2B mutations in West syndrome and intellectual disability with focal epilepsy. *Ann. Neurol.* 75, 147–154.
8. Petrovski, S., Wang, Q., Heinzen, E.L., Allen, A.S., and Goldstein, D.B. (2013). Genic intolerance to functional variation and the interpretation of personal genomes. *PLoS Genet.* 9, e1003709.
9. Gulsuner, S., Walsh, T., Watts, A.C., Lee, M.K., Thornton, A.M., Casadei, S., Rippey, C., Shahin, H., Nimgaonkar, V.L., Go, R.C., et al.; Consortium on the Genetics of Schizophrenia (COGS); PAARTNERS Study Group (2013). Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. *Cell* 154, 518–529.
10. Iossifov, I., Ronemus, M., Levy, D., Wang, Z., Hakker, I., Rosenbaum, J., Yamrom, B., Lee, Y.H., Narzisi, G., Leotta, A., et al. (2012). De novo gene disruptions in children on the autistic spectrum. *Neuron* 74, 285–299.
11. O’Roak, B.J., Vives, L., Girirajan, S., Karakoc, E., Krumm, N., Coe, B.P., Levy, R., Ko, A., Lee, C., Smith, J.D., et al. (2012). Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. *Nature* 485, 246–250.
12. Rauch, A., Wieczorek, D., Graf, E., Wieland, T., Ende, S., Schwarzmayr, T., Albrecht, B., Bartholdi, D., Beygo, J., Di Donato, N., et al. (2012). Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. *Lancet* 380, 1674–1682.
13. Sanders, S.J., Murtha, M.T., Gupta, A.R., Murdoch, J.D., Raubeson, M.J., Willsey, A.J., Ercan-Sencicek, A.G., DiLullo, N.M., Parikhshak, N.N., Stein, J.L., et al. (2012). De novo mutations revealed by whole-exome sequencing are strongly associated with autism. *Nature* 485, 237–241.
14. Zaidi, S., Choi, M., Wakimoto, H., Ma, L., Jiang, J., Overton, J.D., Romano-Adesman, A., Bjornson, R.D., Breitbart, R.E., Brown, K.K., et al. (2013). De novo mutations in histone-modifying genes in congenital heart disease. *Nature* 498, 220–223.
15. Carvill, G.L., Weckhuysen, S., McMahon, J.M., Hartmann, C., Møller, R.S., Hjalgrim, H., Cook, J., Geraghty, E., O’Roak, B.J., Petrou, S., et al. (2014). GABRA1 and STXPB1: novel genetic causes of Dravet syndrome. *Neurology* 82, 1245–1253.
16. Xu, B., Ionita-Laza, I., Roos, J.L., Boone, B., Woodruff, S., Sun, Y., Levy, S., Gogos, J.A., and Karayiorgou, M. (2012). De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. *Nat. Genet.* 44, 1365–1369.
17. Kalscheuer, V.M., Tao, J., Donnelly, A., Hollway, G., Schwinger, E., Kübart, S., Menzel, C., Hoeltzenbein, M., Tommerup, N., Eyre, H., et al. (2003). Disruption of the serine/threonine kinase 9 gene causes severe X-linked infantile spasms and mental retardation. *Am. J. Hum. Genet.* 72, 1401–1411.
18. Ogiwara, I., Ito, K., Sawaishi, Y., Osaka, H., Mazaki, E., Inoue, I., Montal, M., Hashikawa, T., Shike, T., Fujiwara, T., et al. (2009). De novo mutations of voltage-gated sodium channel α 1 gene SCN2A in intractable epilepsies. *Neurology* 73, 1046–1053.
19. Saito, H., Kato, M., Mizuguchi, T., Hamada, K., Osaka, H., Tohyama, J., Uruno, K., Kumada, S., Nishiyama, K., Nishimura, A., et al. (2008). De novo mutations in the gene encoding STXPB1 (MUNC18-1) cause early infantile epileptic encephalopathy. *Nat. Genet.* 40, 782–788.
20. Darnell, J.C., Van Driesche, S.J., Zhang, C., Hung, K.Y., Mele, A., Fraser, C.E., Stone, E.F., Chen, C., Fak, J.J., Chi, S.W., et al. (2011). FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. *Cell* 146, 247–261.
21. Blake, J.A., Bult, C.J., Eppig, J.T., Kadin, J.A., and Richardson, J.E.; Mouse Genome Database Group (2014). The Mouse Genome Database: integration of and access to knowledge about the laboratory mouse. *Nucleic Acids Res.* 42 (Database issue), D810–D817.
22. Neale, B.M., Kou, Y., Liu, L., Ma’ayan, A., Samocha, K.E., Sabo, A., Lin, C.F., Stevens, C., Wang, L.S., Makarov, V., et al. (2012). Patterns and rates of exonic de novo mutations in autism spectrum disorders. *Nature* 485, 242–245.
23. Fromer, M., Pocklington, A.J., Kavanagh, D.H., Williams, H.J., Dwyer, S., Gormley, P., Georgieva, L., Rees, E., Palta, P., Ruderfer, D.M., et al. (2014). De novo mutations in schizophrenia implicate synaptic networks. *Nature* 506, 179–184.

24. Ferguson, S.M., Brasnjo, G., Hayashi, M., Wölfel, M., Collesi, C., Giovedi, S., Raimondi, A., Gong, L.W., Ariel, P., Paradise, S., et al. (2007). A selective activity-dependent requirement for dynamin 1 in synaptic vesicle endocytosis. *Science* *316*, 570–574.
25. Torre, E., McNiven, M.A., and Urrutia, R. (1994). Dynamin 1 antisense oligonucleotide treatment prevents neurite formation in cultured hippocampal neurons. *J. Biol. Chem.* *269*, 32411–32417.
26. Marks, B., Stowell, M.H., Vallis, Y., Mills, I.G., Gibson, A., Hopkins, C.R., and McMahon, H.T. (2001). GTPase activity of dynamin and resulting conformation change are essential for endocytosis. *Nature* *410*, 231–235.
27. Damke, H., Binns, D.D., Ueda, H., Schmid, S.L., and Baba, T. (2001). Dynamin GTPase domain mutants block endocytic vesicle formation at morphologically distinct stages. *Mol. Biol. Cell* *12*, 2578–2589.
28. Boumil, R.M., Letts, V.A., Roberts, M.C., Lenz, C., Mahafey, C.L., Zhang, Z.W., Moser, T., and Frankel, W.N. (2010). A missense mutation in a highly conserved alternate exon of dynamin-1 causes epilepsy in fitful mice. *PLoS Genet.* *6*, 6.
29. Gassmann, M., Shaban, H., Vigot, R., Sansig, G., Haller, C., Barbieri, S., Humeau, Y., Schuler, V., Müller, M., Kinzel, B., et al. (2004). Redistribution of GABAB(1) protein and atypical GABAB responses in GABAB(2)-deficient mice. *J. Neurosci.* *24*, 6086–6097.
30. Knobloch, M., Braun, S.M., Zurkirchen, L., von Schoultz, C., Zamboni, N., Araúzo-Bravo, M.J., Kovacs, W.J., Karalay, O., Suter, U., Machado, R.A., et al. (2013). Metabolic control of adult neural stem cell activity by Fasn-dependent lipogenesis. *Nature* *493*, 226–230.
31. Balschun, D., Wolfer, D.P., Bertocchini, F., Barone, V., Conti, A., Zuschratter, W., Missiaen, L., Lipp, H.P., Frey, J.U., and Sorrentino, V. (1999). Deletion of the ryanodine receptor type 3 (RyR3) impairs forms of synaptic plasticity and spatial learning. *EMBO J.* *18*, 5264–5273.
32. Carvill, G.L., Regan, B.M., Yendle, S.C., O’Roak, B.J., Lozovaya, N., Bruneau, N., Burnashev, N., Khan, A., Cook, J., Geraghty, E., et al. (2013). GRIN2A mutations cause epilepsy-aphasia spectrum disorders. *Nat. Genet.* *45*, 1073–1076.
33. Lesca, G., Rudolf, G., Bruneau, N., Lozovaya, N., Labalme, A., Boutry-Kryza, N., Salmi, M., Tsintsadze, T., Addis, L., Motte, J., et al. (2013). GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. *Nat. Genet.* *45*, 1061–1066.
34. Zhu, X., Need, A.C., Petrovski, S., and Goldstein, D.B. (2014). One gene, many neuropsychiatric disorders: lessons from Mendelian diseases. *Nat. Neurosci.* *17*, 773–781.